ECSP109935A - Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k - Google Patents
Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3kInfo
- Publication number
- ECSP109935A ECSP109935A EC2010009935A ECSP109935A ECSP109935A EC SP109935 A ECSP109935 A EC SP109935A EC 2010009935 A EC2010009935 A EC 2010009935A EC SP109935 A ECSP109935 A EC SP109935A EC SP109935 A ECSP109935 A EC SP109935A
- Authority
- EC
- Ecuador
- Prior art keywords
- mtor
- morfoline
- quinasa
- pi3k
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Un compuesto de fórmula(I) o una sal farmacéuticamente aceptable del mismo, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia, por ejemplo en el tratamiento de enfermedad proliferativa tal como cáncer y particularmente una enfermedad mediada por una quinasa mTOR quinasa y/o una más enzimas PI13K.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94853907P | 2007-07-09 | 2007-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP109935A true ECSP109935A (es) | 2010-03-31 |
Family
ID=39791229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010009935A ECSP109935A (es) | 2007-07-09 | 2010-02-03 | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k |
Country Status (22)
Country | Link |
---|---|
US (1) | US8138183B2 (es) |
EP (1) | EP2176238B1 (es) |
JP (1) | JP5508260B2 (es) |
KR (1) | KR20100042280A (es) |
CN (1) | CN101809002B (es) |
AR (1) | AR070079A1 (es) |
AT (1) | ATE554075T1 (es) |
AU (1) | AU2008273891B2 (es) |
BR (1) | BRPI0814688A2 (es) |
CA (1) | CA2692720A1 (es) |
CL (1) | CL2008003940A1 (es) |
CO (1) | CO6251364A2 (es) |
CR (1) | CR11200A (es) |
DO (1) | DOP2010000012A (es) |
EA (1) | EA018708B1 (es) |
EC (1) | ECSP109935A (es) |
ES (1) | ES2385692T3 (es) |
HK (1) | HK1142906A1 (es) |
NI (1) | NI201000002A (es) |
PE (1) | PE20100138A1 (es) |
WO (1) | WO2009007750A1 (es) |
ZA (1) | ZA200909224B (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0814818A2 (pt) * | 2007-07-09 | 2019-09-10 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica |
US8415376B2 (en) | 2008-05-30 | 2013-04-09 | Amgen Inc. | Inhibitors of PI3 kinase |
ES2529205T3 (es) | 2009-03-13 | 2015-02-17 | Cellzome Limited | Derivados de pirimidina como inhibidores de mTOR |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
JP5680639B2 (ja) | 2009-07-02 | 2015-03-04 | サノフイ | 新規6−モルホリン−4−イル−ピリミジン−4−(3h)−オン誘導体、およびakt(pkb)リン酸化阻害剤としてのこの医薬調製物 |
CA2767064C (fr) | 2009-07-02 | 2017-11-07 | Sanofi | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
MX2012005023A (es) | 2009-10-30 | 2012-06-19 | Ariad Pharma Inc | Metodos y composiciones para tratar cancer. |
EP2992878A1 (en) | 2010-02-03 | 2016-03-09 | Signal Pharmaceuticals, LLC | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
US9249129B2 (en) | 2010-03-04 | 2016-02-02 | Cellzome Limited | Morpholino substituted urea derivatives as mTOR inhibitors |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
ES2612492T3 (es) | 2010-12-28 | 2017-05-17 | Sanofi | Nuevos derivados de piridiminas, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT (PKB) |
WO2012136622A1 (en) | 2011-04-04 | 2012-10-11 | Cellzome Limited | Dihydropyrrolo pyrimidine derivatives as mtor inhibitors |
BR112013027500A2 (pt) | 2011-04-29 | 2017-01-10 | Selecta Biosciences Inc | liberação controlada de imunossupressores de nanotransportadores sintéticos |
CN105039520A (zh) | 2011-08-03 | 2015-11-11 | 西格诺药品有限公司 | 作为lkb1状态的预测性生物标志物的基因表达谱的鉴定 |
BR112014006743A8 (pt) | 2011-09-21 | 2018-01-09 | Cellzome Ltd | composto, uso de um composto, e, método para tratar, controlar, retardar ou impedir uma ou mais condições |
CA2850166C (en) | 2011-09-27 | 2019-12-03 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
AU2012320465B2 (en) | 2011-10-07 | 2016-03-03 | Cellzome Limited | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors |
FR2994572B1 (fr) * | 2012-08-17 | 2015-04-17 | Centre Nat Rech Scient | Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
CA2901696C (en) * | 2013-02-19 | 2021-04-13 | Amgen Inc. | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
US9758495B2 (en) | 2013-03-14 | 2017-09-12 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
TW201527300A (zh) | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 關於1-乙基-7-(2-甲基-6-(1H-1,2,4-***-3-基)吡啶-3-基)-3,4-二氫吡并[2,3-b]吡-2(1H)-酮之醫藥調配物、方法、固態型式及使用方法 |
US9358232B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
WO2014172426A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
JP6382948B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのtorキナーゼ阻害剤及びシチジン類似体を含む組合せ療法 |
BR112015026297B1 (pt) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit |
CA2908353C (en) | 2013-04-17 | 2021-11-02 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
US9937169B2 (en) | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
CN105283175A (zh) | 2013-05-03 | 2016-01-27 | 西莱克塔生物科技公司 | 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子 |
CN113831345A (zh) | 2013-05-29 | 2021-12-24 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
CN111228509A (zh) | 2014-01-03 | 2020-06-05 | 豪夫迈·罗氏有限公司 | 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及其作为血脑屏障穿梭物的应用 |
EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
CN106687476B (zh) * | 2014-06-26 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 抗brdu抗体及使用方法 |
DK3177612T3 (da) | 2014-08-04 | 2022-05-16 | Nuevolution As | Eventuelt fusionerede heterocyclylsubstituerede derivater af pyrimidin, der er anvendelige til behandling af inflammatoriske, metaboliske, onkologiske og autoimmune sygdomme |
CN107073050A (zh) | 2014-09-07 | 2017-08-18 | 西莱克塔生物科技公司 | 用于减弱基因治疗抗病毒转移载体免疫应答的方法和组合物 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
EP3630116B1 (en) | 2017-05-26 | 2024-05-01 | The Board Of Regents Of The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
JP7282045B2 (ja) | 2017-06-22 | 2023-05-26 | セルジーン コーポレイション | B型肝炎ウイルス感染を特徴とする肝細胞癌の治療 |
AU2018301696B8 (en) | 2017-07-13 | 2023-03-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ATR kinase |
US10800774B2 (en) | 2017-08-17 | 2020-10-13 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ATR kinase |
US10894052B2 (en) | 2018-03-16 | 2021-01-19 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ATR kinase |
JP2021098692A (ja) | 2019-12-20 | 2021-07-01 | ヌエヴォリューション・アクティーゼルスカブNuevolution A/S | 核内受容体に対して活性の化合物 |
JP2023519605A (ja) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
AU2021245397A1 (en) | 2020-03-31 | 2022-10-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
CN111646985A (zh) * | 2020-06-01 | 2020-09-11 | 江苏集萃分子工程研究院有限公司 | 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3922735A1 (de) | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
JP3810017B2 (ja) * | 2000-04-27 | 2006-08-16 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
JP2004524279A (ja) | 2000-11-10 | 2004-08-12 | エフ.ホフマン−ラ ロシュ アーゲー | ピリミジン誘導体、及びニューロペプチドy受容体リガンドとしてのその使用 |
AU2003295776B2 (en) | 2002-11-21 | 2011-05-12 | Novartis Vaccines And Diagnostics, Inc. | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
EP1626725A4 (en) | 2003-05-29 | 2006-06-14 | Synta Pharmaceuticals Corp | Heterocyclic compounds for the prevention and treatment of disorders associated with excessive bone formation |
GB0415367D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415365D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
AU2005304393B2 (en) * | 2004-11-10 | 2012-09-27 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
US7863270B2 (en) | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
AU2006313456B2 (en) | 2005-05-20 | 2011-06-23 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
DE102005024494A1 (de) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Cyanopyrimidinen |
MX2007016066A (es) | 2005-07-01 | 2008-03-10 | Irm Llc | Derivados de bencimidazol sustituidos por pirimidina como inhibidores de cinasa de proteina. |
JPWO2007013691A1 (ja) | 2005-07-29 | 2009-02-12 | 武田薬品工業株式会社 | スピロ環化合物 |
WO2007027855A2 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
JP2007091649A (ja) | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
JP4531027B2 (ja) | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2007041358A2 (en) | 2005-09-30 | 2007-04-12 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
CN101801971A (zh) | 2005-09-30 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作janus激酶抑制剂的脱氮嘌呤 |
GB2431156A (en) * | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
DK1945631T3 (da) | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer |
JPWO2007063868A1 (ja) | 2005-11-29 | 2009-05-07 | 東レ株式会社 | アリールメチレンウレア誘導体及びその用途 |
GB0525083D0 (en) * | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525080D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
CA2635997A1 (en) * | 2006-01-11 | 2007-07-19 | Astrazeneca Ab | Morpholino pyrimidine derivatives and their use in therapy |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
WO2007089768A2 (en) | 2006-01-30 | 2007-08-09 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
EP2008210A1 (en) | 2006-03-15 | 2008-12-31 | Csir | Modulation of phosphoryl transferase activity of glutamine synthetase |
JP5243696B2 (ja) | 2006-03-17 | 2013-07-24 | 田辺三菱製薬株式会社 | ベンゼン誘導体 |
EP2003131A4 (en) | 2006-04-04 | 2009-12-16 | Taisho Pharmaceutical Co Ltd | AMINOPYRROLIDINE COMPOUND |
AU2007240496A1 (en) | 2006-04-19 | 2007-11-01 | Novartis Ag | Indazole compounds and methods for inhibition of CDC7 |
WO2007126043A1 (ja) | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | チアゾール環を含むカルボン酸誘導体の医薬用途 |
GB0610909D0 (en) | 2006-06-05 | 2006-07-12 | Merck Sharp & Dohme | Therapeutic treatment |
AU2007269540B2 (en) | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
AU2007287428B2 (en) * | 2006-08-24 | 2011-08-11 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
WO2008023180A1 (en) * | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
US20080234262A1 (en) * | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
CN101790525A (zh) | 2007-04-12 | 2010-07-28 | 霍夫曼-拉罗奇有限公司 | 药物化合物 |
WO2009007751A2 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
-
2008
- 2008-07-08 WO PCT/GB2008/050548 patent/WO2009007750A1/en active Application Filing
- 2008-07-08 AT AT08776183T patent/ATE554075T1/de active
- 2008-07-08 BR BRPI0814688A patent/BRPI0814688A2/pt not_active IP Right Cessation
- 2008-07-08 KR KR1020107002942A patent/KR20100042280A/ko not_active Application Discontinuation
- 2008-07-08 CN CN2008801062258A patent/CN101809002B/zh not_active Expired - Fee Related
- 2008-07-08 JP JP2010515602A patent/JP5508260B2/ja not_active Expired - Fee Related
- 2008-07-08 CA CA 2692720 patent/CA2692720A1/en not_active Abandoned
- 2008-07-08 EP EP08776183A patent/EP2176238B1/en active Active
- 2008-07-08 ES ES08776183T patent/ES2385692T3/es active Active
- 2008-07-08 US US12/668,056 patent/US8138183B2/en not_active Expired - Fee Related
- 2008-07-08 EA EA201000091A patent/EA018708B1/ru not_active IP Right Cessation
- 2008-07-08 AU AU2008273891A patent/AU2008273891B2/en not_active Ceased
- 2008-12-19 PE PE2008002157A patent/PE20100138A1/es not_active Application Discontinuation
- 2008-12-30 AR ARP080105784A patent/AR070079A1/es unknown
- 2008-12-30 CL CL2008003940A patent/CL2008003940A1/es unknown
-
2009
- 2009-12-23 ZA ZA2009/09224A patent/ZA200909224B/en unknown
-
2010
- 2010-01-08 DO DO2010000012A patent/DOP2010000012A/es unknown
- 2010-01-08 CR CR11200A patent/CR11200A/es not_active Application Discontinuation
- 2010-01-08 NI NI201000002A patent/NI201000002A/es unknown
- 2010-02-03 EC EC2010009935A patent/ECSP109935A/es unknown
- 2010-02-09 CO CO10014081A patent/CO6251364A2/es not_active Application Discontinuation
- 2010-10-04 HK HK10109461.9A patent/HK1142906A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20100042280A (ko) | 2010-04-23 |
AU2008273891A1 (en) | 2009-01-15 |
EA018708B1 (ru) | 2013-10-30 |
CO6251364A2 (es) | 2011-02-21 |
ES2385692T3 (es) | 2012-07-30 |
JP2010533160A (ja) | 2010-10-21 |
NI201000002A (es) | 2010-10-12 |
CN101809002A (zh) | 2010-08-18 |
HK1142906A1 (en) | 2010-12-17 |
PE20100138A1 (es) | 2010-03-20 |
EP2176238A1 (en) | 2010-04-21 |
BRPI0814688A2 (pt) | 2017-06-06 |
ZA200909224B (en) | 2011-05-25 |
CN101809002B (zh) | 2013-03-27 |
ATE554075T1 (de) | 2012-05-15 |
JP5508260B2 (ja) | 2014-05-28 |
WO2009007750A1 (en) | 2009-01-15 |
CR11200A (es) | 2010-06-17 |
AR070079A1 (es) | 2010-03-10 |
CL2008003940A1 (es) | 2010-09-24 |
DOP2010000012A (es) | 2010-01-31 |
AU2008273891B2 (en) | 2012-01-12 |
EP2176238B1 (en) | 2012-04-18 |
US20100249131A1 (en) | 2010-09-30 |
EA201000091A1 (ru) | 2010-06-30 |
CA2692720A1 (en) | 2009-01-15 |
US8138183B2 (en) | 2012-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
NI201000003A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
UY30759A1 (es) | Compuestos quimicos | |
DOP2011000203A (es) | Derivados de pirimidin indol para el tratamiento de cancer | |
CL2011003082A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa. | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
SV2011003939A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
CO6290656A2 (es) | Derivados heterociclicos de urea y metodos de uso de los mismos -211 | |
UY31918A (es) | Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
UY29092A1 (es) | Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
UY28271A1 (es) | Compuestos químicos | |
UY31141A1 (es) | Compuestos de piperidina y sus usos | |
CL2010001488A1 (es) | Proceso para preparar 2,4-dioxo-1,2,4-tetrahidropirido[2,3-d]pirimidin-7-il-fenil sustituido y 2,4-bis[3-metilmorfolin-4-il]pirido[2,3-d]pirimidin-7-il-fenil-sustituido; sal fumarato de {5-[2,4-bis[(3s)-3-metilmorfolin-4-il]pirido[2,3-d]pirimidin-7-il]-2-metoxifenil}metanol; composicon farmaceutica; y uso para tratar el cancer. | |
UY31864A (es) | Derivados de urea hetericíclica y métodos de uso de los mismos-332 | |
UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
CU20100004A7 (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
CU20100003A7 (es) | Derivados trisustituídas de pirimidina para el tratamiento de enfermedades proliferativas |